European Journal of Clinical Pharmacology

, Volume 74, Issue 11, pp 1427–1436 | Cite as

Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study

  • Lanfranco PellesiEmail author
  • Manuela Licata
  • Patrizia Verri
  • Daniele Vandelli
  • Federica Palazzoli
  • Filippo Marchesi
  • Maria Michela Cainazzo
  • Luigi Alberto Pini
  • Simona Guerzoni
Pharmacokinetics and Disposition



The recent release of a medical cannabis strain has given a new impulse for the study of cannabis in Italy. The National Health Service advises to consume medical cannabis by vaporizing, in decoction or oil form. This is the first study that explores the pharmacokinetics and tolerability of a single oral dose of cannabis as decoction (200 ml) or in olive oil (1 ml), as a first step to improve the prescriptive recommendations.


This is a single-center, open-label, two-period crossover study designed to assess the pharmacokinetics and tolerability of oral cannabis administered to 13 patients with medication overuse headache (MOH). A liquid chromatography tandem-mass spectrometry (LC-MS/MS) method was conducted for the quantification of THC, CBD, 11-OH-THC, THC-COOH, THC-COOH-glucuronide, THCA-A, and CBDA. Blood pressure, heart rate, and a short list of symptoms by numerical rating scale (NRS) were assessed.


Decoctions of cannabis showed high variability in cannabinoids content, compared to cannabis oil. For both preparations, THCA-A and CBDA were the most widely absorbed cannabinoids, while THC and CBD were less absorbed. The most important differences concern the bioavailability of THC, higher in oil (AUC0–24 7.44, 95% CI 5.19, 9.68) than in decoction (AUC0–24 3.34, 95% CI 2.07, 4.60), and the bioavailability of CBDA. No serious adverse events were reported.


Cannabis decoction and cannabis oil showed different pharmacokinetic properties, as well as distinct consequences on patients. This study was performed in a limited number of patients; future studies should be performed to investigate the clinical efficacy in larger populations.


Cannabinoids Oral cannabis Cannabis decoction Cannabis oil Pharmacokinetics Headache 



We sincerely thank the staff and patients of Medical Toxicology and Headache Centre of Modena, who made possible the realization of the study.

Compliance with ethical standards

The study was approved by the Ethical Committee of Modena (protocol n. 41/2017) and completed in accordance with the ethical standards of the Helsinki Declaration. Written informed consent was obtained from all patients prior to study participation.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2018_2516_MOESM1_ESM.pdf (476 kb)
ESM 1 (PDF 476 kb)
228_2018_2516_MOESM2_ESM.pdf (98 kb)
ESM 2 (PDF 97.9 kb)
228_2018_2516_MOESM3_ESM.pdf (276 kb)
ESM 3 (PDF 275 kb)
228_2018_2516_MOESM4_ESM.pdf (121 kb)
ESM 4 (PDF 120 kb)


  1. 1.
    Baron EP (2015) Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache 55:885–916CrossRefPubMedGoogle Scholar
  2. 2.
    Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234–246CrossRefPubMedGoogle Scholar
  3. 3.
    Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 357:2456–2473CrossRefGoogle Scholar
  4. 4.
    Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360CrossRefPubMedGoogle Scholar
  5. 5.
    Andrade C (2016) Cannabis and neuropsychiatry, 2: the longitudinal risk of psychosis as an adverse outcome. J Clin Psychiatry 77:e739–e742CrossRefPubMedGoogle Scholar
  6. 6.
    Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, Hopfer C (2014) Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. Drug Alcohol Depend 140:137–144CrossRefPubMedGoogle Scholar
  7. 7.
    Grella CE, Rodriguez L, Kim T (2014) Patterns of medical marijuana use among individuals sampled from medical marijuana dispensaries in Los Angeles. J Psychoactive Drugs 46:263–272CrossRefGoogle Scholar
  8. 8.
    Harvey DJ (1991) Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR (ed) Biochemistry and physiology of substance abuse, Vol III. CRC Press, Boca Raton, pp 279–365Google Scholar
  9. 9.
    Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 34:352–363CrossRefPubMedGoogle Scholar
  10. 10.
    Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416CrossRefPubMedGoogle Scholar
  11. 11.
    Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770–1804CrossRefPubMedGoogle Scholar
  12. 12.
    Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303–320CrossRefPubMedGoogle Scholar
  13. 13.
    Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V (2009) Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. J Mass Spectrom 44:1423–1433CrossRefPubMedGoogle Scholar
  14. 14.
    Dussy FE, Hamberg C, Luginbühl M, Schwerzmann T, Briellmann TA (2005) Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. Forensic Sci Int 149:3–10CrossRefPubMedGoogle Scholar
  15. 15.
    Jung J, Kempf J, Mahler H, Weinmann W (2007) Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS. J Mass Spectrom 42:354–360CrossRefPubMedGoogle Scholar
  16. 16.
    Website: Decreto 9 Novembre 2015: Funzioni di Organismo statale per la cannabis previsto dagli articoli 23 e 28 della convenzione unica sugli stupefacenti del 1961, come modificata nel 1972. Available at:;jsessionid=p1rnwNujUKlqQ5azhAQ95A__.NTC-AS3-GURI2A. Accessed 30 Dec 2017
  17. 17.
    Website: Attuazione della legge regionale n. 11 del 17 luglio 2014 e del Decreto Ministeriale 9 novembre 2015 inerenti l’uso medico dei preparati vegetali a base di cannabis sativa. Available at: Accessed 30 Dec 2017
  18. 18.
    Romano LL, Hazekamp A (2013) Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 1:1–11Google Scholar
  19. 19.
    Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S (2017) Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clin Chem Lab MedGoogle Scholar
  20. 20.
    Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRefGoogle Scholar
  21. 21.
    Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, Vandelli MA, Forni F, Cannazza G (2017) Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. J Pharm Biomed Anal 150:25–32CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Prog Biomed 99:306–314CrossRefGoogle Scholar
  23. 23.
    Kandasamy R, Dawson CT, Craft RM, Morgan MM (2018) Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat. Eur J Pharmacol 818:271–277CrossRefPubMedGoogle Scholar
  24. 24.
    Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R (2007) Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol 113:85–90CrossRefPubMedGoogle Scholar
  25. 25.
    Hazekamp A, Verpoorte R (2006) Structure elucidation of the tetrahydrocannabinol complex with randomly methylated beta-cyclodextrin. Eur J Pharm Sci 29:340–347CrossRefPubMedGoogle Scholar
  26. 26.
    Carcieri C, Tomasello C, Simiele M, De Nicolò A, Avataneo V, Canzoneri L, Cusato J, Di Perri G, D'Avolio A (2018) Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol 70(1):143–149CrossRefPubMedGoogle Scholar
  27. 27.
    Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, Ciccarese M, Zappaterra M (2012) Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain 13(8):677–684CrossRefPubMedGoogle Scholar
  28. 28.
    Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ (2017) Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol 41:83–99CrossRefPubMedGoogle Scholar
  29. 29.
    Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS (2011) Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218:443–457CrossRefPubMedGoogle Scholar
  30. 30.
    Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K (2011) Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:165–170CrossRefPubMedGoogle Scholar
  31. 31.
    Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, Luedi M, Drewe J (2012) Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med 78:686–691CrossRefPubMedGoogle Scholar
  32. 32.
    Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L (2011) Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull 34:774–778CrossRefPubMedGoogle Scholar
  33. 33.
    De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168:79–102CrossRefPubMedGoogle Scholar
  34. 34.
    Rock EM, Kopstick RL, Limebeer CL, Parker LA (2013) Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 170:641–648CrossRefPubMedGoogle Scholar
  35. 35.
    Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456–1470CrossRefPubMedGoogle Scholar
  36. 36.
    Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM (2016) Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. Psychopharmacology 233:243–254CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Lanfranco Pellesi
    • 1
    Email author
  • Manuela Licata
    • 2
  • Patrizia Verri
    • 2
  • Daniele Vandelli
    • 2
  • Federica Palazzoli
    • 2
  • Filippo Marchesi
    • 2
  • Maria Michela Cainazzo
    • 1
  • Luigi Alberto Pini
    • 1
    • 3
  • Simona Guerzoni
    • 1
  1. 1.Medical Toxicology, Headache and Drug Abuse CenterUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Forensic Toxicology Laboratory, Department of Diagnostic, Clinical and Public Health MedicineUniversity of Modena and Reggio EmiliaModenaItaly
  3. 3.Centre for Neuroscience and NeurotechnologyUniversity of Modena and Reggio EmiliaModenaItaly

Personalised recommendations